Carbovir is a novel carbocyclic nucleoside which has been shown to have potent in vitro activity against human immunodeficiency virus, the causative agent of acquired immunodeficiency syndrome. Sprague-Dawley male rats were used to investigate the pharmacokinetics and bioavailability of carbovir. Six rats received carbovir (20 mg/kg of body weight) through the jugular vein, and blood samples were collected through the femoral vein 2, 5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, and 240 min after the dose. Four of these rats also received a 60-mg/kg oral dose of carbovir, and a similar blood sampling schedule was followed. Whole-blood samples were prepared by solid-phase extraction, and the carbovir concentration in the samples was analyzed by reversed-phase high-pressure liquid chromatography. The profile of carbovir concentration in blood versus time after the intravenous dose was biexponential, with a very rapid distribution phase. Terminal elimination half-life was 21.4 + 4.37 min, and total body clearance was 55.2 13.8 ml/min per kg, which was within the range of the hepatic blood flow. The volume of distribution at steady state was 1,123 ± 250 ml/kg. The blood/plasma ratio and the plasma protein binding of carbovir in rat blood were determined in vitro by ultrafiltration. The plasma protein binding of carbovir was only 20% and was not concentration dependent. However, the blood/plasma ratio decreased significantly as concentration increased, indicating saturable binding sites in erythrocytes. After the oral dose, the terminal half-life was 81.0 ± 67.6 min, indicating that oral carbovir followed "flip-flop" kinetics, with absorption being much slower than elimination of the drug from the body. Oral bioavailability was 0.101 ± 0.035. Double peaks were present in the concentration-time profile for each rat receiving the oral dose, indicating either a delay in stomach emptying of the drug or slow dissolution of precipitated carbovir in the stomach and upper small intestine.
Carbovir (carbocyclic 2',3'-didehydro-2',3'-dideoxyguanosine; NSC-614846) is a novel carbocyclic guanosine derivative which has been shown to have potent in vitro activity against human immunodeficiency virus (6; R. Vince, M. Hua, J. Brownell, S. Daluge, F. Lee, W. M. Shannon, G. C. Lavelle, J. Qualls, 0. Weislow, R. Kiser, P. G. Cannonico, R. Schultz, V. L. Narayanan, J. G. Mayo, R. H. Shoemaker, and M. R. Boyd, Biochem. Biophys. Res. Commun., in press). Carbovir inhibited human immunodeficiency virus replication and human immunodeficiency virus-induced cytopathic effects in human T-lymphoblastoid cells (lines ATH8, CEM, and MT-2) with a MIC for 50% of strains tested of 0.16 to 0.19 ,ug/ml. In contrast, cytotoxicity was observed at 50% inhibitory concentrations ranging from 35.0 to 60.5 ,ug/ml in the three cell lines (5a, 6) . Because of its potential promise in the treatment of acquired immunodeficiency syndrome, the preclinical pharmacology and toxicology of carbovir are being investigated. This paper is the first report of the pharmacokinetics of carbovir in an animal model, Sprague-Dawley rats.
(Preliminary results of this work were presented at the Third Annual Meeting of the American Association of Pharmaceutical Scientists, 30 October to 3 November 1988, Orlando, Fla.) MATERIALS AND METHODS Chemicals. Carbovir and the internal standard for the high-pressure liquid chromatography (HPLC) assay, carbo-* Corresponding author. cyclic 2',3'-dideoxyguanosine ( Fig. 1) , were synthesized by methods that will be reported elsewhere (R. Vince and M. Hua, submitted for publication). Triethylamine (gold label) was purchased from Aldrich Chemical Co., Inc. (Milwaukee, Wis.). HPLC-grade ammonium phosphate was obtained from J. T. Baker Chemical Co. (Phillipsburg, N.J. Preliminary findings indicated that carbovir reached an equilibrium between plasma and erythrocytes within this period. After the 2 h, the blood was centrifuged and the plasma was removed. A 200-pl volume of each plasma sample was extracted by the solid-phase extraction method described above. The remainder of the plasma was bubbled with CO2 to adjust the pH, and then 400 p.l was placed into a Centrifree micropartition system (Amicon Corp., Danvers, Mass.) and centrifuged at 1,500 x g for 25 min at 37°C. The filtrate was extracted by the solid-phase extraction method, and the concentrations of carbovir in the plasma and the plasma filtrate were determined by comparison to an extracted standard curve of 0.625 to 10 ,ug/ml determined with plasma. The blood/plasma ratio was determined by dividing the spiked concentration of carbovir in blood by the measured concentration in plasma. The free fraction of carbovir in plasma was determined by dividing the concentration in the plasma filtrate by the measured concentration in plasma. The hematocrit was determined and the free fraction of carbovir in blood and the erythrocyte/plasma ratio were calculated as described by Gibaldi and Perrier (1) . Analysis of variance with the procedure of Scheffe was carried out on the blood/plasma ratio, free fraction of carbovir in plasma and in blood, and erythrocyte/plasma ratio to determine whether these variables were concentration dependent. A P value of <0.05 was considered significant.
Pharmacokinetic analysis. The area under the concentration-time curve (AUC) was determined by the trapezoidal rule, with the area from the last measured concentration to infinity estimated as the last concentration divided by the estimated terminal elimination rate constant. The terminal elimination rate constant was determined by linear regression of the terminal portion of the concentration-time profile. The elimination-phase half-life was calculated by dividing 0.693 by the elimination rate constant. Total body clearance and the volume of distribution at steady state were calculated by a noncompartmental approach (1). Maximum concentration of carbovir in blood and the time in which this maximum was reached were determined by observation of the concentration-time profile. The concentration-time curve after the oral dose displayed "flip-flop" kinetics, so the terminal rate constant was assumed to be the absorption rate constant. The elimination rate constant after the oral dose was therefore determined by the method of residuals (1). The absorption-phase half-life was calculated by dividing 0.693 by the absorption rate constant. Oral bioavailability was determined by dividing the AUC after an oral dose by the AUC after an intravenous dose, corrected for the administered dose (1) .
A compartmental analysis was also carried out on the concentration-time profile of carbovir in blood after an intravenous dose. The concentration-time data were fitted to a two-compartment model by PCNONLIN (5) . The distribution-phase and elimination-phase half-lives and the volume of distribution in the postdistribution phase were calculated from the primary and secondary pharmacokinetic parameters generated by PCNONLIN. The volume of the central compartment was obtained directly from the PCNONLIN output.
Statistical comparisons of half-lives were made with the paired Student t test. A P value of <0.05 was considered significant.
RESULTS
With intensive sampling at early intervals after an intravenous dose, the concentration-time profile of carbovir displayed two-compartment pharmacokinetic characteristics. Figure 2A depicts was very rapid (4.9 ± 4.9 min), with a slower terminal elimination-phase half-life (15.6 ± 2.9 min) ( Table 2 ). There was no significant difference among the elimination halflives, whether determined compartmentally or noncompartmentally.
Rat A was administered a 20-mg/kg oral dose; carbovir was almost undetectable in the blood of this animal. The next four rats therefore received 60-mg/kg oral doses of Figure 2B depicts mean data for the four rats and clearly shows that the terminal phase was longer than that for rats given intravenous carbovir ( Fig. 2A ). (Table 3 ). Figure 3 shows the concentration-time profiles in rat B after oral and intravenous dosing; the double peaks after the oral dose are more clearly seen than in the presentation of mean data. Oral bioavailability was 0.101 ± 0.035. Table 4 presents the results of the study of equilibration of carbovir in blood and plasma protein binding. The blood/ plasma ratios for carbovir at 5.0 and 10.0 ,ug/ml (1.16 ± 0.067 and 1.11 0.027, respectively) were significantly lower than that for carbovir at 1.0 ,ug/ml (1.35 ± 0.052). The erythrocyte/plasma ratios followed the same pattern. While the free fraction of carbovir in plasma did not change over the concentration range studied, the free fraction in blood was significantly higher at 5.0 and 10.0 jxg/ml (0.692 ± 0.070 and 0.735 ± 0.026, respectively) than at 1.0 ,ug/ml (0.605 ± 0.046). Although three of the four parameters showed significant differences when results for carbovir at 1.0 ,g/ml were compared with those for carbovir at 5.0 or 10.0 ,ug/ml, there were no significant differences among variables when the 5.0-,ug/ml data were compared with the 10.0-tug/ml data.
DISCUSSION
Carbovir is undergoing extensive preclinical testing to ascertain its usefulness as a treatment of acquired immunodeficiency syndrome. Like other nucleosides, such as 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC), carbovir is rapidly removed from the body after an intravenous dose (2, 3) . In humans, the total body clearance of AZT is approximately 1.3 + 0.3 liters/h per kg, a value which approaches that of hepatic blood flow, and the terminal elimination half-life is 1.1 + 0.2 h (3). In BFD1 mice, the total body clearance of DDC is 30.5 ml/min per kg, with a terminal elimination half-life of 69 min (2). The total body clearance of DDC is 9.6 to 11.8 ml/min per kg in the rhesus monkey, with an elimination half-life of 102 to 114 min (2). The total body clearance of carbovir, 55.2 ± 13.8 mllmin per kg, is within the range of liver blood flow in rats (40 to 60 ml/min per kg), but as with other high-clearance compounds, the liver may be only one of several potential sites of elimination. If the terminal elimination half-life of carbovir in humans is similar to that in rats (21.4 min), then intravenous drug administration will most likely be done by continuous infusion. It must be noted, however, that the elimination of xenobiotics by rats and mice is generally more rapid than in humans (4) . The volume of distribution of carbovir at steady state indicates considerable distribution outside the vascular space, as noted for AZT (3) .
Although the plasma protein binding of carbovir was concentration independent over the range of carbovir concentrations in plasma observed in the present study, the distribution into and binding within erythrocytes appeared to be concentration dependent. As the concentration of carbovir in blood increased, the free fraction in blood increased significantly and the erythrocyte/plasma and blood/plasma ratios decreased. Saturable binding within the erythrocytes is a likely explanation. In this study, in which whole blood was assayed and pharmacokinetic observations were based on blood data, the saturable binding in blood was of little kinetic consequence. However, in future clinical studies, in which the biological fluid assayed is likely to be plasma or serum, the interpretation of plasma pharmacokinetic data must be approached cautiously. Since blood is the medium perfusing the eliminating organs, concentration-dependent changes in carbovir distribution within the blood might lead to changes in the disposition of the compound. These changes would not be immediately apparent from the plasma data, since plasma protein binding appeared to be independent of concentration. On the other hand, if carbovir is a compound with a high extraction ratio with respect to the liver, its clearance would be dependent only on hepatic blood flow, and changes in blood binding might be of little concern. Until more is known about the site(s) of indicated by its capacity factor determined in a reversedphase HPLC assay (Remmel et al., in pres), and the greater lipophilicity of AZT may contribute to its enhanced oral bioavailability.
For each rat receiving oral carbovir, double peaks were observed in the concentration-time profile. It is unlikely that the peaks were due to enterohepatic recycling, since the absorption from the gastrointestinal tract is relatively low and reabsorption of recycled drug would not contribute significantly to the drug concentration in the blood. More likely explanations for the double peaks include delayed stomach emptying or erratic dissolution of precipitated carbovir. To diminish potential effects on metabolism, the rats were not subjected to fasting prior to the oral dosing, and food in the stomach may have contributed to the delayed emptying into the small intestine. In a comparison of DDC absorption in fasting and nonfasting mice, a slightly higher bioavailability was observed in the nonfasting animals, which was attributed to decreased gastrointestinal motility resulting from the presence of food (2) . Alternatively, the carbovir may have precipitated from the alkaline medium in which it was administered when it entered the acidic environment of the stomach and upper intestinal tract. Subsequent dissolution may have been slow and erratic. If the absorption of carbovir is inherently poor because of its lack of lipophilicity, delaying stomach emptying or dissolution may provide a means of enhancing overall absorption.
